CanSino Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,121	1,329	2,023	2,822	3,465	5,645
Short-Term Investments	328.79	326.32	-	-	-	275.2
Trading Asset Securities	960.6	987.97	1,182	1,308	2,482	1,862
Cash & Short-Term Investments	2,410	2,644	3,204	4,130	5,947	7,783
Cash Growth	-21.95%	-17.50%	-22.41%	-30.55%	-23.59%	52.19%
Accounts Receivable	815.7	782.88	737.62	636.88	855.49	157.93
Other Receivables	5.08	43.41	44.79	3.98	0.54	19.15
Receivables	820.78	862.62	818.73	640.87	856.03	177.08
Inventory	401.09	347.85	283.41	352.85	677.78	875.62
Prepaid Expenses	-	-	-	0.25	-	-
Other Current Assets	59.36	-15.38	-24.03	57	249.59	454.49
Total Current Assets	3,692	3,839	4,282	5,181	7,730	9,290
Property, Plant & Equipment	2,580	2,611	2,641	3,013	3,069	2,218
Long-Term Investments	160.84	162.09	483.71	446.56	50.12	45.31
Other Intangible Assets	191.52	188.75	115.49	144.15	220.92	172.12
Long-Term Deferred Tax Assets	205.51	211.55	205.39	207.86	196.41	-
Long-Term Deferred Charges	134.92	137.93	172.21	88.4	51.95	26.19
Other Long-Term Assets	26.77	27.34	57.99	237.53	150.37	122.42
Total Assets	6,991	7,178	7,958	9,319	11,469	11,874
Accounts Payable	53.42	50.44	62.47	103.97	253.12	842.57
Accrued Expenses	144.24	456.29	400.08	454.55	407.25	362.44
Short-Term Debt	69.84	73.22	377.35	883.97	1,530	990.68
Current Portion of Long-Term Debt	139.22	245.31	514.82	509.17	45.77	90.11
Current Portion of Leases	-	5.43	9.99	64.63	48.76	31.18
Current Income Taxes Payable	7.25	5.12	4.66	0.54	3	29.14
Current Unearned Revenue	19.13	18.23	14.69	3.57	1.48	193.22
Other Current Liabilities	465.66	190.98	302.68	544.9	635.52	322.08
Total Current Liabilities	898.76	1,045	1,687	2,565	2,925	2,861
Long-Term Debt	945.46	956.95	1,099	1,066	878.01	40
Long-Term Leases	7.23	7.62	12.68	175.18	198.29	222.85
Long-Term Unearned Revenue	213.72	214.38	250.3	216.72	222.35	201.48
Long-Term Deferred Tax Liabilities	-	-	-	-	-	0.56
Other Long-Term Liabilities	-	-	-	8.49	-	-
Total Liabilities	2,065	2,224	3,048	4,031	4,223	3,326
Common Stock	247.04	247.04	247.45	247.45	247.45	247.45
Additional Paid-In Capital	5,178	5,165	6,577	6,574	6,608	6,598
Retained Earnings	-499.51	-459.08	-1,819	-1,440	42.71	1,150
Treasury Stock	-	-	-95.62	-106.17	-150.17	-
Comprehensive Income & Other	0.19	0.19	0.22	-0.18	0.12	-
Total Common Equity	4,926	4,954	4,910	5,275	6,748	7,995
Minority Interest	-	-	-	12.81	497.51	552.84
Shareholders' Equity	4,926	4,954	4,910	5,287	7,246	8,548
Total Liabilities & Equity	6,991	7,178	7,958	9,319	11,469	11,874
Total Debt	1,162	1,289	2,013	2,699	2,701	1,375
Net Cash (Debt)	1,249	1,355	1,191	1,431	3,246	6,408
Net Cash Growth	13.03%	13.79%	-16.79%	-55.91%	-49.34%	28.90%
Net Cash Per Share	4.82	5.35	4.81	5.80	13.14	25.91
Filing Date Shares Outstanding	247.04	247.04	249.18	247.04	246.77	247.45
Total Common Shares Outstanding	247.04	247.04	249.18	247.04	246.77	247.45
Working Capital	2,793	2,794	2,596	2,616	4,805	6,428
Book Value Per Share	19.94	20.05	19.70	21.35	27.35	32.31
Tangible Book Value	4,734	4,765	4,794	5,130	6,527	7,823
Tangible Book Value Per Share	19.16	19.29	19.24	20.77	26.45	31.61
Buildings	-	1,294	1,025	978.89	729.03	724.68
Machinery	-	878.09	773.61	1,189	1,050	537.75
Construction In Progress	-	1,021	1,268	1,114	1,342	820.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.